Last reviewed: June 26, 2026

Last updated: June 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Wegovy, has demonstrated significant weight loss outcomes in large-scale clinical trials. Patients using semaglutide have achieved an average weight loss of 15 to 22 percent of their baseline body weight within 68 weeks. Understanding realistic expectations helps you evaluate whether this treatment aligns with your health goals.

Start your GLP-1 program with PlexusDx

One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider takes it from there.

Start your intake →

Clinical Trial Weight Loss Results for Semaglutide

The STEP clinical trial program enrolled over 4,500 adults with obesity or overweight status to measure semaglutide's effectiveness. Participants receiving the highest maintenance dose lost an average of 15 percent of their body weight compared to 2.6 percent in the placebo group. These results represent one of the most substantial weight reductions observed in obesity medicine over the past decade.

Weight loss typically accelerates between weeks 12 and 52 of treatment, then plateaus slightly as the body adapts. A 200-pound person losing 15 percent would drop approximately 30 pounds, while a 250-pound individual might lose around 37 pounds over the trial period. Individual outcomes depend on consistent medication use, dietary modifications, and physical activity levels.

Factors That Influence Your Personal Weight Loss Outcome

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR and FTO — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Starting dose, adherence to the medication schedule, and willingness to make dietary changes all influence weight loss magnitude. Patients who combine semaglutide with reduced calorie intake and regular exercise consistently achieve greater outcomes than those relying on medication alone. Age, baseline metabolism, insulin resistance status, and previous weight loss attempts also contribute to individual variation in results.

Timeline: When to Expect Noticeable Weight Loss Changes

Most patients observe initial appetite suppression within the first two weeks of starting semaglutide, though visible weight changes may take three to four weeks to appear. By week eight, many people report losing 3 to 5 percent of their baseline weight. Significant changes—defined as 10 percent or more body weight reduction—typically occur between weeks 12 and 24 of consistent treatment.

Dose escalation follows a gradual protocol to minimize gastrointestinal side effects while optimizing weight loss. Your dose may need to increase over time to maintain effectiveness as your body adapts, but your price won't increase at PlexusDx—compounded semaglutide injection remains flat at $189/mo (or $149/mo on the 6-month plan) regardless of dose level. Patience during the first month is important; early results don't predict final outcomes, and metabolic changes continue throughout the treatment period.

PlexusDx Semaglutide vs. Brand-Name Wegovy: Access and Cost

PlexusDx compounds semaglutide through licensed 503A compounding pharmacies, offering the same active ingredient as Wegovy at a significantly lower cost. Compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan), compared to brand-name Wegovy costs that often exceed $900 monthly without insurance. PlexusDx serves all 50 states, requires no insurance, charges no membership fee, and accepts HSA/FSA funds for eligible accounts.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight will I personally lose with semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to Wegovy or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What do clinical trials tell us about semaglutide weight loss?

The STEP trials demonstrated that semaglutide produces 15 percent average body weight reduction versus 2.6 percent for placebo over 68 weeks. Peak weight loss typically occurs between weeks 12 and 52, with most significant results appearing in the 12–24 week window when patients combine medication with dietary and activity modifications.

Is PlexusDx compounded semaglutide as effective as Wegovy?

Yes—PlexusDx uses the identical active ingredient (semaglutide) compounded in licensed 503A pharmacies as brand-name Wegovy. The difference is cost and access: starting at $149/month with no insurance required, no membership fees, and availability in all 50 states, compared to Wegovy's typical $900+ monthly price tag.

Are there safety concerns with semaglutide weight loss therapy?

Common side effects include nausea, constipation, and appetite loss—most mild and transient during dose escalation. Rare serious risks include pancreatitis and thyroid concerns; discuss personal or family thyroid history with your provider before starting. Clinical trial data supports semaglutide's safety profile when used as prescribed under medical supervision.

How does genetic testing improve my semaglutide results?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake

~60 seconds · $0 charged until your provider approves